On purpose: delivering a branded customer experience people love von Smith, Shaun, Milligan, Andy

Volltext

Interior Resistance von Adams, Rod, Milligan, Andy, Simpkins, Nigel

Volltext

NEXT GENERATION von Milligan, Andy

Volltext

Does it matter when famous UK brands are not British-owned? von Milligan, Andy, Shah, Vikas

Volltext

Nucleation in temperate woodland regeneration: dual mycorrhizal Salix facilitate ectomycorrhizal tree establishment von Martius, Lion R., Fielding, Debbie, Brown, Paige, Milligan, Kerri, Turner, Malcolm, Taylor, Andy F. S.

Volltext

Dynamic species distribution models from categorical survey data von Mieszkowska, Nova, Milligan, Gregg, Burrows, Michael T, Freckleton, Rob, Spencer, Matthew, White, Andy

Volltext

G protein–receptor kinases 5/6 are the key regulators of G protein–coupled receptor 35–arrestin interactions von Ganguly, Amlan, Quon, Tezz, Jenkins, Laura, Joseph, Babu, Al-awar, Rima, Chevigne, Andy, Tobin, Andrew B., Uehling, David E., Hoffmann, Carsten, Drube, Julia, Milligan, Graeme

Volltext

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study von HILLMEN, Peter, GRIBBEN, John G, NATHWANI, Amit, VARGHESE, Abraham, COHEN, Dena, RAWSTRON, Andy, OERTEL, Stephan, POCOCK, Christopher F. E, FOLLOWS, George A, MILLIGAN, Donald, SAYALA, Hazem A, MORETON, Paul, OSCIER, David G, DEARDEN, Claire E, KENNEDY, Daniel B, PETTITT, Andrew R

Volltext

Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial a... von Varghese, Abraham M., Howard, Dena R., Pocock, Christopher, Rawstron, Andy C., Follows, George, McCarthy, Helen, Dearden, Claire, Fegan, Christopher, Milligan, Donald, Smith, Alexandra F., Gregory, Walter, Hillmen, Peter

Volltext

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia von Hillmen, Peter, Cohen, Dena R., Cocks, Kim, Pettitt, Andrew, Sayala, Hazem A., Rawstron, Andy C., Kennedy, Daniel B., Fegan, Christopher, Milligan, Don W., Radford, John, Mercieca, Jane, Dearden, Claire, Ezekwisili, Raphael, Smith, Alexandra F., Brown, Julia, Booth, Gillian A., Varghese, Abraham M., Pocock, Christopher

Volltext

Conversion of sensitive data to Observational Medical Outcomes Partnership (OMOP) Common Data Model: Protocol for the development and use of Carrot. (Preprint) von Cox, Samuel, Masood, Erum, Panagi, Vasiliki, Macdonald, Calum, Milligan, Gordon, Horban, Scott, Santos, Roberto, Hall, Chris, Lea, Daniel, Tarr, Simon, Mumtaz, Shahzad, Akashili, Emeka, Rae, Andy, Cole, Christian, Sheikh, Aziz, Jefferson, Emily, Quinlan, Philip Roy

Volltext

Eradication of minimal residual disease improves overall and progression‐free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL 207: a phase II trial... von Varghese, Abraham M., Howard, Dena R., Pocock, Christopher, Rawstron, Andy C., Follows, George, McCarthy, Helen, Dearden, Claire, Fegan, Christopher, Milligan, Donald, Smith, Alexandra F., Gregory, Walter, Hillmen, Peter

Volltext

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL von Hillmen, Peter, Milligan, Donald, Schuh, Anna, McParland, Lucy, Chalmers, Anna, Munir, Tahla, Varghese, Abraham M, Rawstron, Andy C, Allsup, David J, Marshall, Scott, Smith, Alex, Collett, Corinne, Gregory, Walter, Duncombe, Andrew, Cohen, Dena

Volltext

Jack-of-all-trades effects drive biodiversity-ecosystem multifunctionality relationships in European forests von van der Plas, Fons, Manning, Peter, Allan, Eric, Scherer-Lorenzen, Michael, Verheyen, Kris, Wirth, Christian, Zavala, Miguel A, Hector, Andy, Ampoorter, Evy, Baeten, Lander, Barbaro, Luc, Bauhus, Jürgen, Benavides, Raquel, Benneter, Adam, Berthold, Felix, Bonal, Damien, Bouriaud, Olivier, Bruelheide, Helge, Bussotti, Filippo, Carnol, Monique, Castagneyrol, Bastien, Charbonnier, Yohan, Coomes, David, Coppi, Andrea, Bastias, Cristina C, Dawud, Seid Muhie, De Wandeler, Hans, Domisch, Timo, Finér, Leena, Gessler, Arthur, Granier, André, Grossiord, Charlotte, Guyot, Virginie, Hättenschwiler, Stephan, Jactel, Hervé, Jaroszewicz, Bogdan, Joly, Francois-Xavier, Jucker, Tommaso, Koricheva, Julia, Milligan, Harriet, Müller, Sandra, Muys, Bart, Nguyen, Diem, Pollastrini, Martina, Raulund-Rasmussen, Karsten, Selvi, Federico, Stenlid, Jan, Valladares, Fernando, Vesterdal, Lars, Zielínski, Dawid, Fischer, Markus

Volltext

Jack-of-all-trades effects drive biodiversity-ecosystem multifunctionality relationships in European forests von van der Plas, Fons, Manning, Peter, Allan, Eric, Scherer-Lorenzen, Michael, Verheyen, Kris, Wirth, Christian, Zavala, Miguel A, Hector, Andy, Ampoorter, Evy, Baeten, Lander, Barbaro, Luc, Bauhus, Juergen, Benavides, Raquel, Benneter, Adam, Berthold, Felix, Bonal, Damien, Bouriaud, Olivier, Bruelheide, Helge, Bussotti, Filippo, Carnol, Monique, Castagneyrol, Bastien, Charbonnier, Yohan, Coomes, David, Coppi, Andrea, Bastias, Cristina C, Dawud, Seid Muhie, De Wandeler, Hans, Domisch, Timo, Finer, Leena, Gessler, Arthur, Granier, Andre, Grossiord, Charlotte, Guyot, Virginie, Haettenschwiler, Stephan, Jactel, Herve, Jaroszewicz, Bogdan, Joly, Francois-Xavier, Jucker, Tommaso, Koricheva, Julia, Milligan, Harriet, Mueller, Sandra, Muys, Bart, Nguyen, Diem, Pollastrini, Martina, Raulund-Rasmussen, Karsten, Selvi, Federico, Stenlid, Jan, Valladares, Fernando, Vesterdal, Lars, Zielinski, Dawid, Fischer, Markus

Volltext

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group) von Varghese, Abraham M, Cohen, Dena, Pocock, Christopher F.E., Rawstron, Andy, Gregory, Walter M, Smith, Alex, Skinner, Emma, Critchley, Anne, Milligan, Donald, Dearden, Claire E., McCarthy, Helen, Fegan, Chris, Follows, George A, Hillmen, Peter

Volltext

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study von Hillmen, Peter, Gribben, John G., Follows, George A., Milligan, Donald, Sayala, Hazem A., Moreton, Paul, Oscier, David G., Dearden, Claire E., Kennedy, Daniel B., Pettitt, Andrew R., Nathwani, Amit, Cohen, Dena, Rawstron, Andy, Pocock, Christopher F.E.

Volltext

Stadiums, Race, and Water Infrastructure: Flooding on Atlanta's Southside von Davis, Marni, Milligan, Richard, Walter, Andy

Volltext

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Le... von Hillmen, Peter, Gribben, John G., Follows, George A, Milligan, Donald W., Sayala, Hazem A., Moreton, Paul, Oscier, David, Dearden, Claire E., Kennedy, Daniel B., Pettitt, Andrew R., Nathwani, Amit, Cohen, Dena, Gregory, Walter M, Rawstron, Andy C., Hayward, Colin R.W., Pocock, Christopher

Volltext

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL von Hillmen, Peter, Pocock, Christopher, Cohen, Dena, Cocks, Kim, Sayala, Hazem A., Rawstron, Andy, Kennedy, Daniel B., Fegan, Christopher, Milligan, Don W., Dearden, Claire, Smith, Alexandra, Lindop, Emma, Pettitt, Andrew R.

Volltext